On April 27, 2026, Xirun Medical, a frontrunner among domestic brain-computer interface (BCI) rehabilitation companies, revealed the successful closure of a funding round worth tens of millions of yuan. This investment came solely from the Wuxi Liangxi Science and Technology Innovation Industry Fund. Xirun Medical has developed a comprehensive BCI technology framework, amassing over 80 patents in the process. Its offerings have earned triple international certifications from the NMPA, CE, and FDA. The company's invasive BCI technology has undergone numerous clinical trials at Shanghai Huashan Hospital and other esteemed institutions, aiding patients with severe paraplegia in regaining finger motor function. Notably, it has secured the world's inaugural Class III medical device registration certificate for BCIs. In the realm of non-invasive solutions, Xirun Medical has crafted a tiered product lineup tailored for hospital, community, and home settings. The freshly acquired funds will be channeled towards refining the product lineup, expediting clinical registration and market launch, setting up large-scale production facilities, and bolstering its footprint in both domestic and international markets.